At present, programmed death‐1 (PD‐1)/programmed death ligand‐1 (PD‐L1) inhibitors play a very important role in the standard treatment of advanced NSCLC and extensive stage SCLC. Here, CD274 is linked to non-small cell lung carcinoma.